Novel dual agents for advanced prostate cancer
A recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.
Interpreting real-world data in advanced prostate cancer
Current limitations of real-world data available that support the use of novel therapies, including androgen receptor inhibitors, as treatment for advanced prostate cancer.
PSA kinetics in advanced prostate cancer
In response to a presentation from AUA 2021, Dr. Julie N. Graff considers the role of PSA kinetics as prognostic markers in advanced prostate cancer.
Next steps investigating AR inhibitors in advanced prostate cancer
Based on long-term data and clinical experience treating advanced prostate cancer with androgen receptor inhibitors, Drs Julie N. Graff and Benjamin H. Lowentritt suggest ideas for future study.
AR inhibitor treatment selection in nmCRPC
Considerations that factor into which androgen receptor inhibitor is selected as treatment for nonmetastatic castration-resistant prostate cancer.
AR-targeted therapies for nmCRPC
Julie N. Graff, MD, highlights the efficacy associated with the use of androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer.
AR-targeted therapies for mCSPC
Various factors that medical oncologists consider when selecting to treat metastatic castration-sensitive prostate cancer with either apalutamide or enzalutamide.
AR-targeted therapies for advanced prostate cancer
Julie N. Graff, MD, of OHSU Knight Cancer Institute, comments on the impact of the availability of newer-generation androgen receptor inhibitors on treatment outcomes for patients with advanced prostate cancer.
Collaborative approaches to treating advanced prostate cancer
The role of urologists in working with medical oncologists to treat patients with advanced prostate cancer, with special considerations for early referral.
2 Commerce Drive Cranbury, NJ 08512